Literature DB >> 2881316

Transient supression by stress of haloperidol induced catalepsy by the activation of the adrenal medulla.

O P Yntema, J Korf.   

Abstract

Rats were injected with haloperidol (0.5-1.0 mg X kg-1). When the catalepsy score was almost maximal (60 s, measured by the bar-test), the rats were handled, exposed to cold (3 degrees C) or immobilized. After each of these stress procedures the catalepsy was significantly reduced. Handling of adrenalectomized rats gave no such reduction. Infusion of adrenaline (10 nmol X kg-1, given in 15 s), in contrast to that of isoprenaline and phenylephrine (both the same concentration as adrenaline) also reduced the haloperidol induced catalepsy. These findings indicate that neuroleptic catalepsy in rats is not only mediated through central but also through peripheral mechanisms, e.g. by the adrenal medulla.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2881316     DOI: 10.1007/bf00690942

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Central dopaminergic and serotoninergic systems in the regulation of adrenal tyrosine hydroxylase.

Authors:  M Quik; T L Sourkes
Journal:  J Neurochem       Date:  1977-01       Impact factor: 5.372

2.  Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity.

Authors:  C J de Graaf; J Korf
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Tolerance to the behavioral and neurochemical effects of haloperidol and morphine in rats chronically treated with morphine or haloperidol.

Authors:  S K Puri; H Lal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

4.  Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol.

Authors:  H Asper; M Baggiolini; H R Burki; H Lauener; W Ruch; G Stille
Journal:  Eur J Pharmacol       Date:  1973-06       Impact factor: 4.432

Review 5.  Neurotransmitters and central regulation of adrenal functions.

Authors:  T L Sourkes
Journal:  Biol Psychiatry       Date:  1985-02       Impact factor: 13.382

6.  Adrenal and striatal tyrosine hydroxylase activity after methamphetamine.

Authors:  L Y Koda; J W Gibb
Journal:  J Pharmacol Exp Ther       Date:  1973-04       Impact factor: 4.030

7.  The effect of different types of cortical lesions on drug-induced catalepsy in rats: a pharmacological analysis.

Authors:  P Worms; M T Willigens; D Continsouza-Blanc; K G Lloyd
Journal:  Eur J Pharmacol       Date:  1985-07-11       Impact factor: 4.432

Review 8.  Stress hormones: their interaction and regulation.

Authors:  J Axelrod; T D Reisine
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

9.  Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors.

Authors:  P R Sanberg
Journal:  Nature       Date:  1980-04-03       Impact factor: 49.962

10.  Stress-induced neurological impairments in an animal model of parkinsonism.

Authors:  A M Snyder; E M Stricker; M J Zigmond
Journal:  Ann Neurol       Date:  1985-11       Impact factor: 10.422

View more
  3 in total

1.  Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice.

Authors:  M Lazzarini; C Salum; E A Del Bel
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

2.  Correlation between cataleptic freezing and prepulse inhibition of the startle reflex in rats.

Authors:  N N Barykina; T A Alekhina; V F Chugui; O I Petrenko; N K Popova; V G Kolpakov
Journal:  Neurosci Behav Physiol       Date:  2004-05

3.  Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines.

Authors:  C T Chopde; M S Hote; S N Mandhane; A V Muthal
Journal:  J Neural Transm Gen Sect       Date:  1995
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.